Therapy Areas: Autoimmune
FDA approves Johnson & Johnson's IMAAVY (nipocalimab-aahu) to treat warm autoimmune haemolytic anaemia
25 August 2026 - Healthcare products company Johnson & Johnson (NYSE:JNJ) announced on Monday that the US Food and Drug Administration (FDA) has approved IMAAVY (nipocalimab-aahu) for the treatmen...
Antengene's Phase I study of ATG-201 in B cell-related autoimmune diseases approved in Australia
25 August 2026 - Commercial-stage biotech company Antengene Corporation Limited (SEHK:6996.HK) announced on Monday that the Phase I ATTRACT study of its proprietary ATG-201, a CD19/CD3 bispecific T-ce...
Alfasigma to acquire Nordic Pharma, expanding specialty care portfolio
11 August 2026 - Italian pharmaceutical company Alfasigma S.p.A. announced on Tuesday that it has entered into an agreement with SEVER Life Sciences B.V. to acquire 100% of Nordic Group B.V. and its s...
European Commission approves RINVOQ for severe alopecia areata
29 July 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Wednesday it has received European Commission approval for RINVOQ (upadacitinib) to treat adults and adolescents aged 12 and ove...
AbCellera and Vertex agree collaboration to develop multispecific T-cell engagers
29 July 2026 - Clinical-stage biotechnology company AbCellera Biologics Inc (Nasdaq:ABCL) announced on Wednesday that it has entered into a collaboration with biopharmaceutical company Vertex Pharmace...
AbelZeta's C-CAR168 registrational Phase II trial in refractory Lupus Nephritis granted FDA clearance
28 July 2026 - Clinical-stage biopharmaceutical company AbelZeta Pharma Inc announced on Monday the receipt of US Food and Drug Administration (FDA) clearance under its Regenerative Medicine Advanced ...